心源性休克患者经导管主动脉瓣置换术的结局
本研究基于STS/ACC TVT注册研究,分析2015年6月至2022年9月使用SAPIEN 3/SAPIEN 3 Ultra球囊扩张瓣膜行TAVR的患者。倾向匹配分析显示心源性休克与更高的院内(9.9% vs. 2.7%)、30天(12.9% vs. 4.9%)和1年(29.7% vs. 22.6%)死亡率相关;30天后两组1年死亡率相似(HR 1.07,95%CI 0.95-1.21)。
要点
- 心源性休克患者TAVR术后30天内死亡率显著高于无休克者。
- 存活过30天的休克患者后续1年死亡风险与无休克者无显著差异。
- 1年存活者功能分级和生活质量明显改善。
核心结论
- TAVR是合并心源性休克的主动脉瓣狭窄患者安全有效的治疗方式。
- TAVR后存活超过30天的患者死亡率与无心源性休克者相似。
研究设计与样本
- 基于STS/ACC TVT注册研究的回顾性观察性研究。
- 纳入2015年6月至2022年9月使用SAPIEN 3和SAPIEN 3 Ultra球囊扩张瓣膜行TAVR的患者。
- 心源性休克定义为:TVT注册表24小时内编码为休克,和/或术前使用正性肌力药或机械循环支持装置,和/或TAVR前24小时内心脏骤停。
- 对照组为其他所有行TAVR的患者。
主要发现
- 倾向匹配分析中,心源性休克与更高的院内死亡率(9.9% vs. 2.7%)、30天死亡率(12.9% vs. 4.9%)和1年死亡率(29.7% vs. 22.6%)相关。
- 30天里程碑分析后,两组1年死亡风险相似(HR 1.07,95%CI 0.95-1.21)。
- 1年存活者中89%为NYHA I/II级,KCCQ评分改善+50。
- 多变量分析中,高龄(HR 1.02,95%CI 1.02-1.03)、外周动脉疾病(HR 1.25,95%CI 1.06-1.47)、既往ICD植入(HR 1.37,95%CI 1.07-1.77)、透析(HR 2.07,95%CI 1.69-2.53)、免疫抑制状态(HR 1.33,95%CI 1.05-1.69)和NYHA III/IV级症状(HR 1.50,95%CI 1.06-2.12)与1年死亡率独立相关。
- 瓣膜成功植入率97.9%,VARC-3技术成功率94.5%。
临床怎么用
- 对于合并心源性休克的主动脉瓣狭窄患者,TAVR可作为治疗选择。
- 术后30天是关键风险窗口,需加强监护和支持。
- 存活过30天的患者预后与无休克者相当,应积极管理。
局限性
- 观察性研究设计,可能存在残余混杂。
- 心源性休克定义基于注册数据,可能存在编码偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: The safety and efficacy of transcatheter aortic valve replacement (TAVR) with contemporary balloon expandable transcatheter valves in patients with cardiogenic shock (CS) remain largely unknown. In this study, the TAVRs performed for CS between June 2015 and September 2022 using SAPIEN 3 and SAPIEN 3 Ultra bioprosthesis from the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry were analysed. METHODS AND RESULTS: CS was defined as: (i) coding of CS within 24 h on Transcatheter Valve Therapy Registry form; and/or (ii) pre-procedural use of inotropes or mechanical circulatory support devices and/or (iii) cardiac arrest within 24 h prior to TAVR. The control group was comprised of all the other patients undergoing TAVR. Baseline characteristics, all-cause mortality, and major complications at 30-day and 1-year outcomes were reported. Landmark analysis was performed at 30 days post-TAVR. Cox-proportional multivariable analysis was performed to determine the predictors of all-cause mortality at 1 year. A total of 309 505 patients underwent TAVR with balloon-expandable valves during the study period. Of these, 5006 patients presented with CS prior to TAVR (1.6%). The mean Society of Thoracic Surgeons score was 10.76 ± 10.4. The valve was successfully implanted in 97.9% of patients. Technical success according to Valve Academic Research Consortium-3 criteria was 94.5%. In a propensity-matched analysis, CS was associated with higher in-hospital (9.9% vs. 2.7%), 30-day (12.9% vs. 4.9%), and 1-year (29.7% vs. 22.6%) mortality compared to the patients undergoing TAVR without CS. In the landmark analysis after 30 days, the risk of 1-year mortality was similar between the two groups [hazard ratio (HR) 1.07, 95% confidence interval (CI) 0.95-1.21]. Patients who were alive at 1 year noted significant improvements in functional class (Class I/II 89%) and quality of life (ΔKCCQ score +50). In the multivariable analysis, older age (HR 1.02, 95% CI 1.02-1.03), peripheral artery disease (HR 1.25, 95% CI 1.06-1.47), prior implantation of an implantable cardioverter-defibrillator (HR 1.37, 95% CI 1.07-1.77), patients on dialysis (HR 2.07, 95% CI 1.69-2.53), immunocompromised status (HR 1.33, 95% CI 1.05-1.69), New York Heart Association class III/IV symptoms (HR 1.50, 95% CI 1.06-2.12), lower aortic valve mean gradient, lower albumin levels, lower haemoglobin levels, and lower Kansas City Cardiomyopathy Questionnaire scores were independently associated with 1-year mortality. CONCLUSION: This large observational real-world study demonstrates that the TAVR is a safe and effective treatment for aortic stenosis patients presenting with CS. Patients who survived the first 30 days after TAVR had similar mortality rates to those who were not in CS.
引用
- Goel, Shah, Jones, et al. Outcomes of transcatheter aortic valve replacement in patients with cardiogenic shock. Eur Heart J. 2023. PMID: 37350747. doi:10.1093/eurheartj/ehad387
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。